Immune cells armed with antibody take on pancreatic cancer
NCT ID NCT03269526
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tested a new treatment called EGFR BATs for people with advanced pancreatic cancer. The treatment uses a patient's own immune cells, armed with a special antibody, to target cancer cells. The study included 22 participants who had already received chemotherapy. The goal was to check safety and see if it could improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EGFR BATs (immune cells armed with a bispecific antibody)
What this could lead to
If successful, this could offer a new treatment option to extend survival for people with advanced pancreatic cancer.
What could go wrong
This is an early-phase trial with only 22 participants, so results may not apply broadly. Side effects from the immune cells are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Virginia
Charlottesville, Virginia, 22903, United States